SBI Okasan Asset Management Co.Ltd. Buys Shares of 1,723 Eli Lilly and Company $LLY

SBI Okasan Asset Management Co.Ltd. acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,723 shares of the company’s stock, valued at approximately $1,859,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. Brighton Jones LLC raised its holdings in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Schnieders Capital Management LLC. lifted its stake in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC bought a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,126.66 on Friday. The company has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 40.02, a PEG ratio of 1.18 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a 50-day simple moving average of $952.15 and a 200 day simple moving average of $1,009.10. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,149.10.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark will restore coverage for Zepbound and begin covering Lilly’s new obesity pill Foundayo, meaning all three major U.S. pharmacy benefit managers now cover Lilly’s full obesity portfolio. That broadens access, supports prescription growth, and strengthens Lilly’s position in the fast-growing weight-loss market. Article Title
• Positive Sentiment: Lilly announced three vaccine acquisitions worth up to about $3.8 billion combined, signaling a strategic expansion beyond obesity and diabetes into infectious disease prevention. Investors may view the deal-making as a long-term growth move that diversifies the pipeline. Article Title
• Positive Sentiment: The company also highlighted strong clinical momentum, including new data for Foundayo, Mounjaro, and retatrutide ahead of the ADA conference. The late-stage results suggest Lilly could keep extending its lead in cardiometabolic care. Article Title
• Positive Sentiment: Several firms reiterated bullish views, including BofA raising its price target and Wolfe Research maintaining an Outperform rating. That reinforces the market’s confidence in Lilly’s earnings and pipeline growth. Article Title
• Neutral Sentiment: Lilly presented at Bernstein’s Strategic Decisions Conference and is set to appear at other healthcare conferences, which keeps attention on management’s outlook but is not, by itself, a major fundamental driver. Article Title
• Negative Sentiment: Some commentary warned that Lilly’s valuation is rich and that Novo Nordisk could still be a strong competitor in the obesity-pill market. That may limit upside if investors become more cautious about how much growth is already priced in. Article Title

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,344.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 1st. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Finally, Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,227.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.